[{"from": "human", "value": "Provide a description of this molecule. [C][N][C][=Branch1][C][=O][C@H1][Branch1][=N][C][O][C][=C][Ring1][Branch2][N][=C][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=N][N][C][=Branch1][Ring2][=N][Ring1][Branch1][C][C][=C][C][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1), with potential anti-inflammatory and immunomodulatory activities. Upon oral administration, eclitasertib disrupts RIPK1-mediated signaling, and may attenuate inflammation and the resulting tissue damage. RIPK1, a signaling protein in the tumor necrosis factor (TNF) receptor pathway, plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition."}]